Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 89

Results For "2022"

1439 News Found

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr
News | July 27, 2022

Aarti Drugs reports consolidated Q1 FY23 PAT at Rs. 34.78 Cr

Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.


SKYCovione will strengthen South Korea position in global COVID-19 vaccine industry, says GlobalData
News | July 27, 2022

SKYCovione will strengthen South Korea position in global COVID-19 vaccine industry, says GlobalData

This will not only strengthen the country’s overall position in the global vaccine industry but also reduce its reliance on foreign vaccines


Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr
News | July 26, 2022

Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr

The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.


Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr
News | July 26, 2022

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr

The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.


GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr
News | July 26, 2022

GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr

GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022


Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey
News | July 26, 2022

Urinary incontinence 2nd biggest reason for limited mobility in elderly: Survey

72.5% elderly feel their generation used to spend more time with their elders, 52.4% feel lonely, shows PAN Health’s Liberty in Life of Older People 2022 survey


Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr
News | July 26, 2022

Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr

Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022


Lupin receives approval from U.S. FDA for Azilsartan Medoxomil Tablets
Drug Approval | July 26, 2022

Lupin receives approval from U.S. FDA for Azilsartan Medoxomil Tablets

The product will be manufactured at Lupin's facility in Nagpur, India.


Cadila Pharma bags ‘Rising Digital Star’ award at DigipharmaX
News | July 26, 2022

Cadila Pharma bags ‘Rising Digital Star’ award at DigipharmaX

The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.


Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets
Drug Approval | July 26, 2022

Zydus receives final approval from the USFDA for Bisoprolol Fumarate Tablets

Bisoprolol Fumarate Tablets are used to treat high blood pressure.